治疗eplerenone的长期效果在患有慢性全移植脏病的儿童中
Esra Baskin1, Meraj Alam Siddiqui2, Kaan Gülleroğlu1
1Department of Pediatric Nephrology, Baskent University Faculty of Medicine, Ankara, Turkey.
Pediatric transplantation
|June 7, 2023
概括
长期给予儿科移植接受者患有慢性异质移植脏病 (CAN) 的eplerenone,稳定了估计的淋巴细胞过率 (eGFR) 和减少了蛋白尿. 这项研究发现没有观察到高胆固醇血症,这表明eplerenone是儿童癌症的安全有效治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 移植免疫学 移植免疫学
- 儿科医学 儿科医学 儿科医学
背景情况:
- 矿物甲类抗体 (MRAs) 在移植接受者中显示出对阿尔多斯激素诱导的损伤的保护作用.
- 关于MRA在儿科移植患者的安全性和疗效的数据有限.
- 慢性异位移植脏病 (CAN) 是儿科脏移植的一个重大问题.
研究的目的:
- 为了研究eplerenone在被诊断为慢性全移植脏病 (CAN) 的儿童的长期影响.
- 评估eplerenone在稳定功能和减少小儿移植接受者的蛋白尿症方面的安全性和有效性.
主要方法:
- 一项涉及26名儿科移植患者的研究,其生物检测证明CAN和eGFR>40mL/min/1.73m2.
- 患者被随机分为两组:第一组 (n=10) 接受了25毫克/天的eplerenone,第二组 (n=16) 没有.
- 结果在36个月内进行了监测,定期进行临床检查和实验室评估.
主要成果:
- 第1组的患者保持了稳定的平均估计球过率 (eGFR),而第2组的患者显示显著下降 (p=0.001).
- 与对照组 (p<0.001) 相比,在eplerenone组 (1组) 中,斑点蛋白与肌素的比率明显较低 (p<0.001).
- 在第一组 (p=0.713) 中,没有观察到与eplerenone相关的高胆血症病例.
结论:
- 长期使用eplerenone有效地抑制了儿科移植患者慢性移植病 (CAN) 的进展.
- 在这种人群中,eplerenone有助于保持稳定的eGFR水平,并降低尿蛋白-肌氨酸比率.
- 埃普莱伦显示出良好的安全性概况,在研究队列中没有观察到高血症.
相关概念视频
01:29Acute Kidney Injury III: Clinical Manifestations
44
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
44
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
01:25Chronic Kidney Disease I: Introduction
46
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
46
01:26Kidney Transplant II: Surgical Procedure
37
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
37
01:11Renal Failure: Dose Adjustments
127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
01:24Chronic Kidney Disease II: Clinical Manifestations
46
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
46